Mr. Andre Larente reports

DIAGNOS, FOLLOWING A SUCCESSFUL PROOF-OF-CONCEPT (POC) PILOT STUDY, IS FINALISING ITS NEW APPLICATION CARA-STROKE TO ADDRESS STROKE PREVENTION AND MANAGEMENT, A MARKET ESTIMATED AT $36 BILLION

Diagnos Inc. is at the final step of the development of its stroke predictor (CARA-ST) based on images of the retina. Following the completion of a successful proof-of-concept pilot study with over 3,000 patients, Diagnos is now ready to proceed with clinical trials.

As per the Centers for Disease Control and Prevention (CDC), strokes are the cause of one out of every 20 deaths, representing a cost of approximately $34-billion (U.S.) per year in the United States. According to the World Health Organization, 15 million people suffer a stroke worldwide each year. Of these, five million die and another five million are permanently disabled. High blood pressure contributes to more than 85 per cent of strokes worldwide. Europe averages approximately 650,000 stroke-related deaths each year.

Hence, early diagnosis and treatment to prevent deaths from stroke are time-sensitive necessities. Stroke prevention devices are currently used to reduce the risk of a recurrent stroke in patients and have been shown to lower the overall risk.

"CARA-ST will be able to predict the viability of developing a stroke condition based on the microcirculation analysis of the retina image of the patient. Diagnos has been developing this technology for the last four years, and, because of the conditions brought on by the COVID-19 pandemic, we were able to expedite the final testing and development of our new application," said Riadh Kobbi, vice-president, data science, at Diagnos.

"According to new reports published by worldwide research institutes, the market size for stroke management will hit over $36-billion by 2023. Diagnos intends to be part of the solution by making available an affordable predictive test to the general public. At Diagnos, we have continued to invest in research and development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (ETS) to ensure we stay ahead of competition worldwide. This year, our new stroke management application will be field tested in multiple countries. For our investors, this groundbreaking test comes at an ideal time in terms of shareholder value creation as the combination of both CARA-DR and CARA-ST tools will be transformational in helping to monitor the health of existing and future CV [cardiovascular] patients," said Andre Larente, president of Diagnos.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based off its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the U.S. Food and Drug Administration (United States), CE (Europe), COFEPRIS (Mexico), and the Saudi Food and Drug Administration (Saudi Arabia).

We seek Safe Harbor.